FIORICET W/ CODEINE (butalbital, acetaminophen, caffeine, and codeine phosphate) by Teva is butalbital, a barbiturate, is a gaba a receptor agonist and may inhibit excitatory ampa receptors. Approved for the symptom complex of tension (or muscle contraction) headache, alternative treatments are inadequate, other non-opioid analgesic. First approved in 1992.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Fioricet w/ Codeine is an oral fixed-dose combination analgesic containing butalbital (barbiturate), acetaminophen, caffeine, and codeine phosphate (weak opioid). It treats tension headaches and muscle contraction headaches when alternative treatments are inadequate. The combination works through multiple mechanisms: barbiturate CNS depression, acetaminophen analgesia, caffeine as a CNS stimulant, and codeine as a mu-opioid agonist.
Mature product approaching loss of exclusivity with moderate competitive pressure (30%); team size likely stable but declining as generic entry accelerates.
Butalbital, a barbiturate, is a GABA A receptor agonist and may inhibit excitatory AMPA receptors. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions. Caffeine is a methylxanthine and CNS stimulant. The exact mechanism…
Barbiturate
Worked on FIORICET W/ CODEINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Fioricet w/ Codeine positions you in a mature, declining product lifecycle focused on defensibility and managed care strategy rather than growth. Career progression is limited; this role is best suited for professionals building experience in LOE management, generic competition mitigation, and pain portfolio rationalization.